A mechanistic approach to understanding oral drug absorption in pediatrics: an overview of fundamentals.

The common phrase 'children are not little adults' is very true also in the field of oral drug administration and absorption. However, in practice, due to the little available data and lack of in-depth understanding, physicians may treat kids as if they were 'little adults', even without being aware of the potential differences and risks. With respect to drug discovery, research and development, an in-depth understanding of the various factors governing age-dependent absorption is crucial when trying to develop a pediatric-tailored oral drug product. In this paper we clarify the various mechanisms that may lead to age-dependent oral drug absorption, we provide an overview of the currently available data, and draw conclusions to the coming years.

[1]  B. Chumpitazi,et al.  Pediatric gastrointestinal motility disorders: challenges and a clinical update. , 2008, Gastroenterology & hepatology.

[2]  O. Dulac,et al.  Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial , 2000, The Lancet.

[3]  Shyam Sundar,et al.  Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.

[4]  M. Benninga,et al.  Pharmacokinetics of a Single Oral Dose of Baclofen in Pediatric Patients With Gastroesophageal Reflux Disease , 2003, Therapeutic drug monitoring.

[5]  W. Rosenfeld,et al.  A study of topiramate pharmacokinetics and tolerability in children with epilepsy. , 1999, Pediatric neurology.

[6]  Carol Taketomo,et al.  Pediatric Dosage Handbook: Including Neonatal Dosing, Drug Administration, & Extemporaneous Preparations , 2009 .

[7]  Y. Vandenplas,et al.  Diagnosis and treatment of gastro‐oesophageal reflux disease in infants and children , 2000, Annals of medicine.

[8]  Denise Thomson,et al.  Standard 6: Age Groups for Pediatric Trials , 2012, Pediatrics.

[9]  P. Levisohn Safety and Tolerability of Topiramate in Children , 2000, Journal of child neurology.

[10]  M. Kukulka,et al.  Age-Dependent Pharmacokinetics of Lansoprazole in Neonates and Infants , 2008, Paediatric drugs.

[11]  Siv Jönsson,et al.  Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms , 2008, Pharmacogenetics and genomics.

[12]  Marsha G Raanan,et al.  Safety and Pharmacodynamics of Lansoprazole in Patients with Gastroesophageal Reflux Disease Aged <1 Year , 2008, Paediatric drugs.

[13]  M. Thomson,et al.  Intestinal Metabolism and Transport of Drugs in Children: The Effects of Age and Disease , 2008, Journal of pediatric gastroenterology and nutrition.

[14]  R. Dimmitt,et al.  Baclofen for the Treatment of Pediatric GERD , 2013, Journal of pediatric gastroenterology and nutrition.

[15]  G. Amidon,et al.  The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. , 2014, Molecular pharmaceutics.

[16]  J. Asconapé The selection of antiepileptic drugs for the treatment of epilepsy in children and adults. , 2010, Neurologic clinics.

[17]  Arik Dahan,et al.  The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  G. Crippen,et al.  Purely in silico BCS classification: science based quality standards for the world's drugs. , 2013, Molecular pharmaceutics.

[19]  I. Kanfer,et al.  Pharmacokinetics of Oral Decongestants , 1993, Pharmacotherapy.

[20]  G. Amidon,et al.  Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. , 2009, Molecular pharmaceutics.

[21]  O. Dulac,et al.  Stiripentol: Efficacy and Tolerability in Children with Epilepsy , 1999, Epilepsia.

[22]  H. Dammann,et al.  Clinical characteristics of roxatidine acetate: a review. , 1988, Scandinavian journal of gastroenterology. Supplement.

[23]  Lawrence X. Yu,et al.  High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. , 2010, Molecular pharmaceutics.

[24]  R. Egan,et al.  Comparative Oral and Topical Decongestant Effects of Phenylpropanolamine and d-Pseudoephedrine , 2001, American journal of rhinology.

[25]  I. Tamai,et al.  Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. , 2011, Journal of pharmaceutical sciences.

[26]  J. Hardcastle,et al.  Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.

[27]  J. W. Poole,et al.  Serum concentrations of ampicillin in newborn infants after oral administration. , 1973, Pediatrics.

[28]  J. Pácha Development of intestinal transport function in mammals. , 2000, Physiological reviews.

[29]  G. Runge,et al.  Investigations on the bacterial flora, pH, and sugar content in the intestinal tract of infants. , 1952, The Journal of pediatrics.

[30]  G. Koren,et al.  Neonatal and pediatric clinical pharmacology. , 2012, Pediatric clinics of North America.

[31]  E. Thiele,et al.  Efficacy and safety of rufinamide in pediatric epilepsy , 2013, Therapeutic advances in neurological disorders.

[32]  D. Wall,et al.  Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation , 2009, Pediatric blood & cancer.

[33]  A. Dahan,et al.  Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations , 2013, PloS one.

[34]  G. Ecker,et al.  Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.

[35]  L. Lázaro,et al.  Fluoxetine pharmacogenetics in child and adult populations , 2012, European Child & Adolescent Psychiatry.

[36]  M. Danhof,et al.  What is the right dose for children? , 2010, British journal of clinical pharmacology.

[37]  A. Dahan,et al.  The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  W. Crom Pharmacokinetics in the child. , 1994, Environmental health perspectives.

[39]  M. Armand,et al.  Enzyme replacement therapy for pancreatic insufficiency: present and future , 2011, Clinical and experimental gastroenterology.

[40]  S. D. de Wildt,et al.  Ontogeny of oral drug absorption processes in children , 2012, Expert opinion on drug metabolism & toxicology.

[41]  S. Abdel‐Rahman,et al.  Pediatric pharmacokinetics: human development and drug disposition. , 2012, Pediatric clinics of North America.

[42]  A. Dahan,et al.  The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  Stewart Cf,et al.  Effect of maturation on drug disposition in pediatric patients. , 1987 .

[44]  G. Kearns,et al.  Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine , 2004, Journal of pediatric gastroenterology and nutrition.

[45]  J. Boos,et al.  Randomized clinical trials in children--ethical and methodological issues. , 2010, Current pharmaceutical design.

[46]  N. Huang,et al.  Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. , 1953, The Journal of pediatrics.

[47]  E. Thiele,et al.  New drugs for pediatric epilepsy. , 2010, Seminars in pediatric neurology.

[48]  P. Lundborg,et al.  Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. , 2000, The Journal of pediatrics.

[49]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[50]  G. Amidon,et al.  Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[51]  T. Glauser,et al.  Topiramate Pharmacokinetics in Infants , 1999, Epilepsia.

[52]  G. Amidon,et al.  Multiple Efflux Pumps Are Involved in the Transepithelial Transport of Colchicine: Combined Effect of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Leads to Decreased Intestinal Absorption Throughout the Entire Small Intestine , 2009, Drug Metabolism and Disposition.

[53]  S. Sundar,et al.  Oral miltefosine for Indian post‐kala‐azar dermal leishmaniasis: a randomised trial , 2013, Tropical medicine & international health : TM & IH.

[54]  R. Guerrini,et al.  Topiramate in the Treatment of Epilepsy - A Review , 2006 .

[55]  R. D. Brown,et al.  Antimicrobial Therapy in Neonates, Infants and Children , 1989, Clinical pharmacokinetics.

[56]  Gordon L Amidon,et al.  The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. , 2010, Journal of pharmaceutical sciences.

[57]  S. Hertz,et al.  Regulatory review of acetaminophen clinical pharmacology in young pediatric patients. , 2012, Journal of pharmaceutical sciences.

[58]  C. Faure,et al.  Pharmacokinetics of Proton Pump Inhibitors in Children , 2005, Clinical pharmacokinetics.

[59]  Viktoriya Ioffe-Dahan,et al.  The Twofold Advantage of the Amorphous Form as an Oral Drug Delivery Practice for Lipophilic Compounds: Increased Apparent Solubility and Drug Flux Through the Intestinal Membrane , 2012, The AAPS Journal.

[60]  A. Matas,et al.  Infant Human Pancreas: A Potential Source of Islet Tissue for Transplantation , 1976, Diabetes.

[61]  J. Fallingborg,et al.  Intraluminal pH of the human gastrointestinal tract. , 1999, Danish medical bulletin.

[62]  G. Kearns,et al.  Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny , 2003, Clinical pharmacology and therapeutics.

[63]  R. de Groot,et al.  Pharmacokinetics of Nelfinavir in Children: Influencing Factors and dose Implications , 2002, Antiviral therapy.

[64]  Stephen S. Hwang,et al.  In Vitro and In Vivo Evaluation of a Once‐Daily Controlled‐Release Pseudoephedrine Product , 1995, Journal of clinical pharmacology.

[65]  A. Dahan,et al.  The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs , 2012, The AAPS Journal.

[66]  L. A. Christensen,et al.  Measurement of Gastrointestinal pH and Regional Transit Times in Normal Children , 1990, Journal of pediatric gastroenterology and nutrition.

[67]  R. Guerrini,et al.  A Pharmacokinetic Study and Correlation with Clinical Response of Rufinamide in Infants with Epileptic Encephalopathies , 2013, Pharmacology.

[68]  G. Amidon,et al.  The H2 Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport , 2009, The AAPS Journal.

[69]  Arik Dahan,et al.  A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. , 2012, Molecular pharmaceutics.

[70]  G. Kearns,et al.  The Bioequivalence of Nizatidine (Axid®) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared with Capsule , 2003, Journal of clinical pharmacology.

[71]  R. V. van Lingen,et al.  Acetaminophen Developmental Pharmacokinetics in Premature Neonates and Infants: A Pooled Population Analysis , 2002, Anesthesiology.

[72]  S. Urien,et al.  Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children , 2006, Antimicrobial Agents and Chemotherapy.

[73]  Hans Lennernäs,et al.  Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. , 2014, Molecular pharmaceutics.

[74]  P D Griffiths,et al.  Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  C. Brandt,et al.  Serum Concentrations of Rufinamide in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication , 2011, Therapeutic drug monitoring.

[76]  Y. Vandenplas Management of paediatric GERD , 2014, Nature Reviews Gastroenterology &Hepatology.

[77]  Arik Dahan,et al.  Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[78]  G. Amidon,et al.  The fraction dose absorbed, in humans, and high jejunal human permeability relationship. , 2012, Molecular pharmaceutics.

[79]  R. Baldassano,et al.  Up-regulation of glutathione S-transferase activity in enterocytes of young children. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[80]  G. Anderson,et al.  Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach , 2009, Pharmacotherapy.

[81]  F. Dimario,et al.  Childhood Head Tremor , 2000, Journal of child neurology.

[82]  Warren Gh,et al.  Serum concentrations of sodium nafcillin in infants during the perinatal period. , 1965 .

[83]  S. Yum,et al.  Efficacy and Tolerability of Topiramate in Children Younger Than 2 Years Old , 2005, Journal of child neurology.

[84]  G. Maira,et al.  Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients , 2003, Cancer Chemotherapy and Pharmacology.

[85]  R. Riccardi,et al.  Role of temozolomide in pediatric brain tumors , 2006, Child's Nervous System.

[86]  Imke H. Bartelink,et al.  Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations , 2006, Clinical pharmacokinetics.

[87]  G. Brown,et al.  Duodenal bile acids in infancy. , 1975, Archives of disease in childhood.

[88]  S. Mahant,et al.  Efficacy and Safety of Proton Pump Inhibitors in the Management of Pediatric Gastroesophageal Reflux Disease , 2013, Pharmacotherapy.

[89]  M. Gersten,et al.  Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  L. Nguyen,et al.  Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. , 2010, Blood.

[91]  A. Hoffman,et al.  Use of a Dynamic in Vitro Lipolysis Model to Rationalize Oral Formulation Development for Poor Water Soluble Drugs: Correlation with in Vivo Data and the Relationship to Intra-Enterocyte Processes in Rats , 2006, Pharmaceutical Research.

[92]  V. Purohit Biopharmaceutic Planning in Pediatric Drug Development , 2012, The AAPS Journal.

[93]  G. Koren,et al.  Back to basics: understanding drugs in children: pharmacokinetic maturation. , 2005, Pediatrics in review.

[94]  R. Guerrini,et al.  Topiramate and its clinical applications in epilepsy , 2006, Expert opinion on pharmacotherapy.

[95]  J. Panetta,et al.  Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors , 2003, Cancer Chemotherapy and Pharmacology.

[96]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[97]  G. Amidon,et al.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. , 2012, Clinical therapeutics.

[98]  J. Beijnen,et al.  Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis , 2012, Antimicrobial Agents and Chemotherapy.

[99]  M. Baker Antidotes for nerve agent poisoning: should we differentiate children from adults? , 2007, Current opinion in pediatrics.

[100]  Brady T. West,et al.  Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[101]  R. Gilbert,et al.  Cisapride treatment for gastro-oesophageal reflux in children. , 2010, The Cochrane database of systematic reviews.

[102]  Takeyuki Sato,et al.  Population Pharmacokinetics of Oral Busulfan in Young Japanese Children Before Hematopoietic Stem Cell Transplantation , 2008, Therapeutic drug monitoring.

[103]  L. Michaud,et al.  Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis , 2001, Alimentary pharmacology & therapeutics.

[104]  S. Cremers,et al.  Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. , 2002, British journal of clinical pharmacology.

[105]  R. Strickley,et al.  Pediatric drugs--a review of commercially available oral formulations. , 2008, Journal of pharmaceutical sciences.

[106]  Mirjam N Trame,et al.  Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children , 2011, Clinical Cancer Research.

[107]  G. Amidon,et al.  MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. , 2010, International journal of pharmaceutics.

[108]  E. Garofalo,et al.  Clinical development of antiepileptic drugs for children , 2011, Neurotherapeutics.

[109]  W. Jusko,et al.  Pharmacokinetics in the infant. , 1994, Environmental health perspectives.

[110]  E. Wirrell,et al.  Specific safety and tolerability considerations in the use of anticonvulsant medications in children , 2012, Drug, healthcare and patient safety.

[111]  A. Iolascon,et al.  Challenges in prescribing drugs for children with cancer. , 2008, The Lancet. Oncology.

[112]  E. Fuseau,et al.  Supporting the recommended paediatric dosing regimen for rufinamide in Lennox–Gastaut syndrome using clinical trial simulation , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[113]  B. Friis‐Hansen WATER DISTRIBUTION IN THE FOETUS AND NEWBORN INFANT , 1983, Acta paediatrica Scandinavica. Supplement.

[114]  M. Morais,et al.  Gastroesophageal reflux disease: exaggerations, evidence and clinical practice. , 2014, Jornal de pediatria.

[115]  J. Rowe,et al.  Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. , 2008, Current drug safety.

[116]  I. Kanfer,et al.  Steady State Pharmacokinetics and Dose‐Proportionality of Phenylpropanolamine in Healthy Subjects , 1990, Journal of clinical pharmacology.

[117]  J. Lantos,et al.  Ethical issues in neonatal and pediatric clinical trials. , 2012, Pediatric clinics of North America.

[118]  Hidefumi Nakamura,et al.  Pharmacokinetics of the H2 Blocker Roxatidine Acetate Hydrochloride in Pediatric Patients, in Comparison with Healthy Adult Volunteers , 2012 .

[119]  Gordon L. Amidon,et al.  Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs , 2009, The AAPS Journal.

[120]  M. Strolin Benedetti,et al.  Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations , 2005, Expert opinion on drug metabolism & toxicology.

[121]  D. Faulds,et al.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. , 1992, Drugs.

[122]  S. Laurberg,et al.  Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system , 2011, BMC gastroenterology.

[123]  G. Koren Therapeutic drug monitoring principles in the neonate , 1997 .

[124]  E. Perucca,et al.  Topiramate Pharmacokinetics in Children and Adults with Epilepsy , 2005, Clinical pharmacokinetics.

[125]  T. Mayer,et al.  Concentrations of Stiripentol in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication , 2012, Therapeutic drug monitoring.

[126]  Vinita B Pai,et al.  Nelfinavir Mesylate: A Protease Inhibitor , 1999, The Annals of pharmacotherapy.

[127]  A. Dahan,et al.  Regional-Dependent Intestinal Permeability and BCS Classification: Elucidation of pH-Related Complexity in Rats Using Pseudoephedrine , 2013, The AAPS Journal.

[128]  A. Dahan,et al.  The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. , 2012, Molecular pharmaceutics.

[129]  W. Garnett Clinical Pharmacology of Topiramate: A Review , 2000, Epilepsia.

[130]  T. Andersson,et al.  Pharmacokinetics of orally administered omeprazole in children , 2000, American Journal of Gastroenterology.

[131]  Jason Gerson,et al.  Ethical considerations in conducting pediatric research. , 2011, Handbook of experimental pharmacology.

[132]  A. Atkinson,et al.  Principles of Clinical Pharmacology , 2001 .

[133]  G. Salvia,et al.  Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[134]  K. Simons,et al.  Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. , 1996, The Journal of pediatrics.

[135]  E. Palumbo Oral miltefosine treatment in children with visceral leishmaniasis: a brief review. , 2008, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.